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Vena caval filters are a widely accepted method of
prevention of pulmonary embolism (PE), and one of
the driving forces for improvement has been ease of per-
cutaneous insertion. This was the impetus for the devel-
opment of the titanium Greenfield filter (TGF), which
used a 12F carrier system as opposed to the 24F system
used for the operative insertion of the original stainless
steel Greenfield filter (SGF). The TGF has proved com-
parable to the SGF in the long term with regard to vena
caval patency (99%) and protection from PE (97%).1,2
Because of design constraints, the guidewire was elimi-
nated during insertion, and this may have been respon-
sible for the 10% incidence of asymmetry of the limbs
that was observed. One possible cause for the asymme-
try was a failure of centering in the cava in the absence
of a guidewire at the time of filter release. Even though
there was no correlation between asymmetry of the
limbs and recurrent embolism, it represented a theoret-
ical opening for small emboli on the basis of experimen-
tal modeling.3 For the guidewire technique to be
restored, a stainless steel filter was designed with a
longer neck that accommodated a guidewire yet only
required a 12F carrier system. The guidewire and a new
flexible carrier also facilitated placement from the left
and right femoral veins.4 The hooks were shortened
from .05 to .035 in, and the vertical direction was
altered in two limbs to accommodate the guidewire
(Table I). Although these design changes were subtle,
there was a potential for adverse effects. This study was
undertaken to evaluate the effects on indications for
placement and effectiveness of the percutaneous steel
Greenfield filter (PSGF). 
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Objective: The percutaneous steel Greenfield filter (PSGF) is similar in appearance to the
titanium Greenfield filter (TGF) but differs in the length and orientation of the attach-
ment hooks and in the over-the-wire delivery system. Because these differences improve
ease of insertion and attachment, they may affect patient outcomes and physician prac-
tices. The purpose of this study was to evaluate the performance of the PSGF relative to
the TGF and to determine whether there had been a change in physician practices.
Methods: The Michigan Filter Registry contains data for a prospective cohort of 2188
patients with Greenfield filters. Procedural and long-term outcomes for patients with a
PSGF were abstracted. These events were compared with rates for Registry patients who
had a TGF. Trends for indication for placement, delivery route, and filter location were
also compared with published series.
Results: Since 1995, 600 PSGFs have been placed in 599 patients. A 1-year mortality
rate of 42% left 349 patients available for annual follow-up, and studies were complet-
ed for 231 (66%). Periprocedural events occurred in 2.5% of cases with associated mor-
bidity in 1.5%. The rate of new pulmonary embolism was 2.6%, and vena caval patency
was 98.3%. The combined rate of new venous thromboembolic events was 12.5%. Left-
sided femoral vein placements increased to 20%, and the major indication for filter place-
ment has become prophylaxis (46%).
Conclusions: The PSGF is similar to the TGF with respect to patient outcomes, and it
provides decreased rates of asymmetry along with excellent fixation. The flexible carrier
system has allowed more frequent access through the left femoral vein. The ease of use
and favorable patient outcomes have resulted in more frequent placement for prophy-
lactic indications. (J Vasc Surg 2000;32:888-93.)
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MATERIAL AND METHODS
The Michigan Filter Registry contains data collect-
ed at the time of filter insertion and annually scheduled
follow-up visits. Data are classified into three cate-
gories: demographic and clinical status at time of filter
placement, details of the placement, and patient and
filter findings at the yearly follow-up visits and
unscheduled hospital admissions. All data are collected
by one reviewer on the basis of the medical record.
Patients are contacted each year with a reminder letter
for their follow-up examination, which includes physi-
cal examination, ultrasound scan of the inferior vena
cava and bilateral lower extremities, and plain radi-
ograph of the abdomen obtained in anteroposterior
and lateral projections. When a patient is reported to
have died, efforts are made to obtain the cause of
death from the hospital record or the next of kin. The
database was queried for all patients with a PSGF as
their primary or secondary device. The reporting stan-
dards for vena caval filters of the International Society
for Cardiovascular Surgery and the Society of
Cardiovascular and Interventional Radiology5,6 were
used to summarize the data. Outcomes were com-
pared with those previously reported or as summarized
from the Registry1 with SAS version 6.12 (SAS
Institute Inc, Cary, NC). χ2 Tests were used for
dichotomous data and t tests or analysis of variance for
continuous outcomes. P values less than .05 were con-
sidered significant.
RESULTS
The PSGF accounts for 31% of database entries
with 600 filters in the 299 women and 300 men
(mean age, 54 years). The mean time for data accru-
al was 26 months. Thirty-day and 1-year mortality
rates were 13% and 42%, respectively. Death was
related to the underlying disease in all but one case.
This patient died 2 days after filter placement with
PE listed as the cause of death. No autopsy was per-
formed. Annual follow-up was obtained in 231
(66%) of 349 eligible patients surviving at 1 year. Of
these, 213 had the revised alternating hook PSGF,
whereas 18 had an earlier version of the device mod-
eled after the TGF hooks, which were recurved to an
angle of 80 degrees. This revision allowed some dis-
tal migration, and therefore, two of the six hooks
were directed downward at an angle of 125 degrees
for further stabilization (Table II).
Patient characteristics. Surgery (22%), trauma
(28%), venous disease (17%), and malignancy (13.5%)
were the most frequently recorded primary diagnoses
(Table III), and contraindication to anticoagulation
(34%) and prophylaxis (46%) comprised 80% of place-
Fig 1. Long-term follow-up of PSGF patients for caval
patency.
Table I. Characteristics of the titanium and steel
percutaneous filters
TGF PSGF
Material Titanium Stainless steel
Hook Modified obtuse Alternating
Filter base diameter 38 mm 32 mm
Height 50 mm 52 mm
Delivery system Steel carrier Flexible carrier
Guidewire No Yes
Table II. Effect on mechanical stability of the
PSGF from modification of the fixation hook
PSGF with PSGF with 
alternating hook standard hook
Migration 0.4% 27%*
Penetration 1% 11%*
Increase filter base 0.4% 5%
Tilt 0.4% 5%
Asymmetry 2% 5%
*P < .05.
Table III. Primary diagnoses among patients with
PSGF
Trauma 28.3%
Surgery 22%
Venous disease 17.2%
Malignancy 13.5%
Cardiac disease 3.2%
Pulmonary disorder 2.8%
History of PE 2.7%
Arterial disease 1.5%
CNS disorder 1.2%
GI 1%
Pregnancy 1%
Other 5.6%
CNS, Central nervous system; GI, gastrointestinal; PE, pul-
monary embolism.
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ment indications (Table IV). Anticoagulants were
used by 282 patients before placement, whereas 266
were anticoagulated subsequently. Filters were most
often placed by radiologists (590 of 599), and all but
two were placed percutaneously. More than 70% were
placed through the right femoral vein and 10%
through the right jugular vein. The flexible delivery
system facilitates placement from the left groin, which
allowed radiologists to use this preferred access. The
number of left femoral vein insertions increased to
20% with no accompanying increase in insertion site
problems. All but two attempts at placement were
successful (99.6%). Filters were placed above the renal
vein in 5% of patients (Table V). Insertion problems
occurred in 16 patients, including incomplete open-
ing, asymmetry, tilt, sheath kinking, and leg crossing.
The postprocedure complication rate was 1.5% with
two hematomas and seven bleeding episodes.
Follow-up summary. Long-term event rates are
based on the 231 patients who had objective follow-
up. Most significantly, recurrent PE was seen in six
patients (2.6%), five of whom were also being anti-
coagulated. Four filters (1.7%) were occluded, on the
basis of absent Doppler scan signal and the inability
to visualize the filter (Fig 1). Ultrasound scan of the
inferior vena cava was indeterminate in 35 patients
because of less than optimal examination results, but
none of these patients had signs or symptoms of caval
occlusion. There were 14 new isolated cases of deep
venous thrombosis (DVT), four cases of DVT that
occurred with PE or caval occlusion and 10 asymp-
tomatic insertion site thromboses for a recurrent
thromboembolism incidence of 12.5%. Abdominal
radiographs were obtained for 223 (97%) of 231
patients. Filter movement greater than 20 mm was
noted in 3% total but in only 1% of the alternating
hook design. Asymmetry was reported in five
patients (2%). Penetration of the vena cava by a filter
limb was suspected in four patients, and computed
tomographic scans of the four confirmed two asymp-
tomatic penetrations.
Sixty-two patients (27%) had lower extremity
edema at follow-up, and 37 used graduated support
stockings to control the symptoms. Ulceration
occurred in six patients (2.6%). Anticoagulation was
used by 76% of the patients at some point between fil-
ter placement and clinical follow-up, and 81 continued
to require anticoagulation at their last examination.
DISCUSSION
Improvements in the mechanical properties of
the Greenfield filter have been achieved by changing
the metal alloy, as with the titanium model, or the
design, as with the PSGF. These modifications added
Fig 2. Changing indications for filter insertion from 1988-1999. The most dramatic increase occurred
in the indication prophylaxis.
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the flexibility needed to fold the device into a smaller
carrier for percutaneous insertion. However, these
changes also reduced the force of attachment to the
vena caval wall, which necessitated a change in hook
configuration. With the TGF, the more obtuse angle
achieved good fixation, but it proved inadequate
when a slightly shorter version was used in the PSGF.
Alternating the hooks in a downward and upward
direction achieved optimal stabilization. Initial expe-
rience with the PSGF was reported in 75 patients
from nine participating institutions with a 30-day fol-
low-up.7 This showed a reduction in the 10% asym-
metry rate seen with the TGF to 5.3% (P = .28) with
no clinical sequelae. There were no recurrent PE
episodes in the abbreviated follow-up, but caval
occlusion was seen in three patients with end-stage
metastatic disease (5%). There was one instance of
probable caval penetration without sequelae. There
was no migration beyond the accepted respiratory
variation limits of 20 mm. An additional report of 47
patients by Johnson et al8 showed a 2% recurrent PE
rate but a 12% (2 of 16) incidence of caval thrombo-
sis. Filter asymmetry was reported in 14 patients. 
The PSGF was never envisioned as an improve-
ment to the TGF but as an alternative. Table I lists
some minor differences in materials and design that
may lead to selection of one over the other in various
situations. There are two major differences: the flexi-
ble carrier and the availability of a guidewire. The
flexible carrier led our radiologists to pursue the left
femoral route in a larger percentage of placements
because they prefer a groin to a neck approach. From
a clinical perspective, this has resulted in fewer inser-
tion-site thromboses. The differences in caval paten-
cy and new DVT are more likely related to the differ-
ences in the patient groups because the rate of pro-
phylactic placements doubled since 1993.
In the current article, we have insertion and follow-
up data on a much larger group of PSGF patients,
which show a reduction in the incidence of asymme-
try from 10% to 2.1% (P = .03). These differences in
rates among reporting centers highlight the need to
develop standard definitions for technical events to
allow adequate comparison. The recurrent rate of PE
with the PSGF is neither clinically nor statistically dif-
ferent than the TGF (3.5%) or the SGF (4%)1,2 (Table
VI). Recurrent PE is an indication for a venacavogram
to visualize the filter that usually has successfully
trapped thrombi but may have propagating thrombus
above it. When this is documented, either lytic thera-
py should be used or a second filter should be insert-
ed in a suprarenal position, as it occurred in one
patient in this series. Filter occlusion occurs from a
large volume of trapped thrombus and was noted pre-
viously in 3.6% of SGF patients, 3.5% of the TGF
patients, and only 1.7% of patients in the current
series. New or recurrent DVT occurred in 17 patients
(7%), whereas 10 (4.3%) had thrombosis of their
insertion site. Aggregating these with the patients
with recurrent PE produces an overall rate of 12.5%
of recurrent thromboembolic disease in this series.
Recurrent thrombosis in filter patients has been erro-
neously attributed to the presence of a filter,9 rather
than the more likely underlying thrombotic disease.
However, most series show even higher recurrence
rates in patients with DVT without filters.10
Two technical problems have been cited in pub-
lished reviews.4,11-14 The first is related to incom-
plete opening of the filter at deployment. Review of
the reports indicated that when the original carrier
was retracted, it failed to completely uncover the fil-
ter hooks. This happened when the carrier length
was at the upper limit of design tolerance. The man-
ufacturer lowered the tolerances, and reports of this
Table IV. Indications for placement of PSGF
Prophylaxis 46%
Contraindication to anticoagulation 34%
Complication with anticoagulation 15%
Recurrent PE 2%
Unknown 3%
Table V. Location and route for PSGF placement
Location
Infrarenal 569 (95%)
Suprarenal 30 (5%)
Route
Left femoral 118 (19.6%)
Right femoral 413 (69%)
Right jugular 61 (10%)
Other 7 (1%)
Table VI. Comparison of outcomes for patients
with percutaneous Greenfield filters
PSGF TGF
New PE 2.6% 3.2%
Caval patency 98.3% 93.2%
New DVT 7.3% 15%*
Insertion site thrombosis 4.3% 8.4%
Migration 1% 1%
Asymmetry 2% 10%*
Fracture 0.3% 0
Ulceration 2% 5%
*P < .05.
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problem declined. The second problem involved
entrapment of guidewires by the filter at deployment
and during other interventional procedures. Design
changes to the PSGF reduced the space between the
struts at the apex of the filter and included an open-
ing for a guidewire. If the wire looped back on itself
or kinked, it could become trapped between the
struts and resist removal. Kaufman et al15 have
reported results from an in vitro study indicating this
occurs with J wires less than 3-mm in circumference.
They recommend that a 15 J guidewire be used
whenever blind central line procedures are per-
formed. Visualization of guidewire extraction at the
time of filter placement, use of fluoroscopy during
line changes in patients with vena caval filters, and
cessation of guidewire pulling when resistance is
encountered until adequate visualization is available
will limit morbidity. 
With improved ease of insertion provided by the
reduced delivery system and the flexible carrier, we
began to see a change in indications because clinicians
seemed more willing to insert a filter than to risk anti-
coagulation in borderline situations. More patients are
receiving filters for “prophylaxis” than for other indi-
cations related to anticoagulation. Where 89 (14%) of
616 filters placed before 1988 were for prophylaxis, 90
of 388 filters placed between 1988 and 1993 were
prophylactic, and in 1999, the percentage rose to 46%
or 276 of 600 filters. The interpretation of prophylax-
is has now broadened to include patients with or with-
out currently documented DVT or PE and those in
whom the filter is used as an adjunct to anticoagula-
tion. The most dramatic increase has been in the pro-
phylactic use of the filter in patients with trauma,
which accounts for 51% of all prophylactic placements
(Fig 2). The evidence supporting this approach has
been based on clinical experience in which a series of
high-risk patients who have trauma with filters were
compared with historical controls.16-18 These high-risk
patients showed excellent protection from use of the
filter, but with PE rates of 1% or less, most patients do
not develop DVT or PE. Therefore, they did not
directly benefit from the procedure. There is a clear
need for a method of risk assessment that will concen-
trate this costly investment in a population of patients
with trauma who are most likely to benefit from it. 
The PSGF is a safe and effective means of pre-
venting PE. Design changes in the delivery of the
device, the fixation hooks, and the apex wires, along
with its record of efficacy, have led to more frequent
prophylactic placements. Continued long-term
study of these patients is warranted to determine the
effects of these modifications. 
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DISCUSSION
Dr Robert Rutherford (Silverthorne, Colo). I have a
few comments before posing four questions to the
authors. As you have heard from the presentation here,
the focus of this paper goes well beyond changing practice
patterns. It brings valuable performance data on the per-
cutaneous stainless steel Greenfield filter, documenting
the performance and what can be expected from this new
technological advance. This may be, in a way, the most
impressive part of the paper. Also significant is the depth
of data in this performance analysis, which is generated by
a registry geared to the new reporting standards for caval
filters. I would hope in the future that reported experi-
ences with this and other caval filters will comply with
these standards and give us equally objective and detailed
disclosure of outcomes. 
I have the following questions for Dr Greenfield. First,
you report a 1-year mortality of 42%, which may not be
surprising, considering the high-risk groups represented,
particularly the trauma group. Is there any way of getting
representative early performance data on some of these
lost patients? If not, do you think the exclusion of these
high-risk cases from the later 1-year follow-up potentially
improves the performance data that you report? 
Second, can you tell us something about the Michigan
Filter Registry? Is it just for Greenfield filters? How many
participating centers are there? Do you analyze the feed-
back to see whether it is representative of a broader
nationwide performance with this new filter?
Third, there are several design changes represented in
the new percutaneous device, and I would like to ask you
how you would rank them in the performance advantages
that you have documented here today. I know there is
reduction from a #24 to a #12 French introducer, the flex-
ible carrier, the over-the-guidewire insertion and release,
and some other subtle design features of the filter itself.
What do you feel are the relative roles they play in how
well this new filter is doing?
Finally, along the same lines, how much do the chang-
ing indications, which are now mostly prophylactic use,
contribute to the better performance of the newer percu-
taneous version? In other words, are the changes in prac-
tice pattern self-generated, or are they a result of the new
improvements in the filter? How much do these changes
in practice influence a better performance, since they are
mostly for prophylactic indications?
Finally, in closing, I would like to add a comment about
the increasing prophylactic use. In your manuscript you
identify, and I quote, “a clear need for a method of risk
assessment that will concentrate on this most costly invest-
ment in a population of trauma patients most likely to ben-
efit from it,” and I would certainly echo this. I would fur-
ther suggest that we need randomized comparisons of out-
comes that include cost-benefit analysis that are stratified for
these new prophylactic indications, particularly trauma, can-
cer patients, and so forth. I enjoyed the paper very much. I
think it brings us valuable and well-analyzed data on the
new filter, as well as characterizing associated practice
changes. Thank you for the privilege of the floor.
Dr Lazar J. Greenfield. Thank you very much for your
insightful questions. Your first question was about the accu-
racy of the information that we have related to patients who
died. Obviously the most accurate information we have is
on patients who die in the hospital since we would have any
subsequent scans, angiograms, or CT, that would have sug-
gested thromboembolic events. For deaths that occur out-
side of the hospital, we have to rely on information that we
get from the family or the referring physicians, and that is,
as you know, quite unreliable. We do try, with all these
patients, to determine whether or not there was any chance
that the patient sustained a pulmonary embolic death or any
death related to the filter, and we have reported any of those
that we thought could have been related.
The second question was about the filter registry. The
Michigan Registry that we maintain is only the Michigan
experience. We do have a few other filters in it, the occa-
sional bird’s nest that the radiologist inserts for the mega
cava. There is a potential difference between our experi-
ence and other institutions in the areas of asymmetry and
tilting because there are no consistent standards. That is
one of the reasons that we were stimulated to develop the
reporting guidelines that have been published.
The next question was the importance of the design
changes. I think that clearly the most significant advantage
was in size of the carrier system, reducing it from #24 to #12
French, allowing for percutaneous insertion. This really made
a dramatic change in the perceived ease of positioning the
device. As far as the other changes, the hook configuration
seems to be most important in terms of the performance of
the device, that is, its long-term stability. 
Finally, your last question, does more prophylactic use
contribute to improved performance? We were concerned
about that. We looked at the embolic events in the pro-
phylactic group alone, which had no evidence of the
thrombotic disorder at the time of placement, and indeed
the recurrent embolism rate was 2.2% in this group as
opposed to 2.4% in the treatment group, showing that
there was very little difference. So there may be an influ-
ence, but so far we have not been able to see it.
